A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

The purpose of this study is to observe and capture demographic characteristics, treatment patterns, and clinical outcomes of interest for patients with PH-ILD to further clinical understanding of the epidemiological landscape and outcomes of the disease and treatment. Study details include: ? This patient registry will follow patients for up to 5 years after enrollment. ? As part of the study, designated assessments in Table 8-1 will be completed for data collection in 6- or 12-month intervals, unless the data are already available via standard of care. ? Approximately 150 patients will be newly initiated on Tyvaso/Tyvaso DPI. Approximately 1000 patients will be enrolled in the registry. No study drug will be used in this study. Patients who are on Tyvaso/Tyvaso DPI (inhaled treprostinil) will receive drug as prescribed by their physician; dosing and titration will be at the discretion of the prescribing physician. Patients with PH-ILD will be followed for up to 5 years. This registry is observational in nature and no study drug will be supplied.

VIVO